ES2043890T3 - Nuevo uso medico. - Google Patents

Nuevo uso medico.

Info

Publication number
ES2043890T3
ES2043890T3 ES88850306T ES88850306T ES2043890T3 ES 2043890 T3 ES2043890 T3 ES 2043890T3 ES 88850306 T ES88850306 T ES 88850306T ES 88850306 T ES88850306 T ES 88850306T ES 2043890 T3 ES2043890 T3 ES 2043890T3
Authority
ES
Spain
Prior art keywords
medical use
new medical
igf
insulin
mammals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88850306T
Other languages
English (en)
Inventor
Linda Fryklund
Hans Arne Hansson
Martin Kanje
Anna Skottner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Kabi Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia AB filed Critical Kabi Pharmacia AB
Application granted granted Critical
Publication of ES2043890T3 publication Critical patent/ES2043890T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METODO PARA MEJORAR LA REGENERACION DE NERVIOS PERIFERICOS SECCIONADOS EN MAMIFEROS Y EN HOMBRES, ADMINISTRANDOLES UNA CANTIDAD SUFICIENTE DE UN FACTOR 1 DE CRECIMIENTO TIPO INSULINICO A UN HUESPED DE MAMIFERO O HUMANO, NECESITADO DE DICHO TRATAMIENTO.
ES88850306T 1987-09-18 1988-09-16 Nuevo uso medico. Expired - Lifetime ES2043890T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8703625A SE8703625D0 (sv) 1987-09-18 1987-09-18 New medical use

Publications (1)

Publication Number Publication Date
ES2043890T3 true ES2043890T3 (es) 1994-01-01

Family

ID=20369616

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88850306T Expired - Lifetime ES2043890T3 (es) 1987-09-18 1988-09-16 Nuevo uso medico.

Country Status (7)

Country Link
US (1) US5068224A (es)
EP (1) EP0308386B1 (es)
AT (1) ATE82507T1 (es)
DE (1) DE3876052T2 (es)
ES (1) ES2043890T3 (es)
GR (1) GR3007092T3 (es)
SE (1) SE8703625D0 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US6440928B1 (en) 1988-12-06 2002-08-27 Colorado State University Research Foundation Method for treating diabetic neuropathy with NGF
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en) 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6723699B1 (en) 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
ZA9010332B (en) * 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
WO1991012018A1 (en) * 1990-02-13 1991-08-22 Gropep Pty. Ltd. Method for treating intestinal diseases
AU637199B2 (en) * 1990-02-13 1993-05-20 Novozymes Biopharma Dk A/S Method for treating intestinal diseases
US5679771A (en) * 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
US5545719A (en) * 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
ES2101865T3 (es) * 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JP3747416B2 (ja) * 1991-11-25 2006-02-22 インスティテュート オブ モレキュラー バイオロジー インコーポレイテッド 哺乳類の神経の増殖を促進する薬物
IT1254706B (it) 1991-12-23 1995-10-09 Fidia Spa Uso terapeutico del ganglioside gm1 nel trattamento del danno al midollo spinale
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
ES2140463T3 (es) * 1992-06-12 2000-03-01 Cephalon Inc Prevencion y tratamiento de la neuropatia periferica.
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US20070078089A1 (en) * 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II
SE9301667D0 (sv) * 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
EP0729361A4 (en) * 1993-11-15 1996-11-06 Celtrix Pharma METHOD FOR TREATING NEUROLOGICAL DISEASES
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5834029A (en) * 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US5916569A (en) * 1997-03-26 1999-06-29 E. Martin Spencer Human erectile dysfunction and methods of treatment
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US7687039B2 (en) * 1998-10-28 2010-03-30 Covaris, Inc. Methods and systems for modulating acoustic energy delivery
PT1141014E (pt) * 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
ES2346185T3 (es) * 2000-08-29 2010-10-13 Aurogen Incorporated Metodo para tratar el sistema nervioso central mediante la administracion de analogos estructurales de igf.
JP4489352B2 (ja) * 2001-02-09 2010-06-23 ジェネンテック， インコーポレイテッド Ｉｇｆ−１の結晶化
ES2387562T3 (es) 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
AU2002303164A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
GB0202906D0 (en) * 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
JP3977162B2 (ja) * 2002-06-21 2007-09-19 株式会社バンダイナムコゲームス キャラクタ情報管理装置、プログラム及び情報記憶媒体
US20060058376A1 (en) * 2003-05-27 2006-03-16 Suntory Limited Composition having autonomic nerve modulating activity and method of use thereof
NZ553057A (en) * 2004-08-30 2009-12-24 Tercica Inc Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
AR059088A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una proteina para esclerosis lateral amiotrofica
JP5993308B2 (ja) 2011-01-26 2016-09-14 雪印メグミルク株式会社 感覚改善剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes

Also Published As

Publication number Publication date
ATE82507T1 (de) 1992-12-15
DE3876052T2 (de) 1993-03-25
SE8703625D0 (sv) 1987-09-18
GR3007092T3 (es) 1993-07-30
EP0308386A1 (en) 1989-03-22
US5068224A (en) 1991-11-26
EP0308386B1 (en) 1992-11-19
DE3876052D1 (de) 1992-12-24

Similar Documents

Publication Publication Date Title
ES2043890T3 (es) Nuevo uso medico.
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
AU6951087A (en) Pump block for interfacing irradiation chamber to photoactivation patient treatment system
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
IT1208343B (it) Siringa dentaria per iniezioni intralegamentarie
MY104992A (en) Composition inducing a binding.
KR950701226A (ko) C-키트 수용체의 리간드 및 그의 사용방법
CY1638A (en) Binding-inducing composition
AU2158688A (en) Use of bezafibrate for treating diabetes
IE871567L (en) Method for treating depression
DE3168248D1 (en) Wound healing compositions
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
DE68916777T2 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
TW217382B (es)
MY103252A (en) Binding-inducing composition
AU7931487A (en) Therapeutic treatment of abnormal cell growth with follicle regulatory protein

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 308386

Country of ref document: ES